Alessio Ardizzone

Alessio Ardizzone is a Tenure Track Researcher (RTT) in Pharmacology (BIOS-11/A, previously BIO/14) at UniCamillus – Saint Camillus International University of Health and Medical Sciences, Rome, Italy.

In July 2019, he earned his Master’s Degree in Pharmaceutical Chemistry and Technology from the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm) at the University of Messina, discussing a thesis entitled “Neuroprotective effects of 2-pentadecyl-2-oxazoline (PEA-OXA) in a model of cerebral ischemia in diabetic rats.”

During his PhD in Applied Biology and Experimental Medicine (35th cycle), awarded with honors at the University of Messina, he investigated the use of natural compounds in preclinical models of gastrointestinal disorders, defending a thesis entitled “Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion.”

During the third year of his PhD, he worked as an Affiliate Researcher at the Institute of Infection, Immunity and Inflammation, University of Glasgow (Scotland, UK), taking part in international projects aimed at elucidating the roles of various cytokines and chemokines in the inflammatory processes underlying atherosclerosis.

From April 2023 to April 2024, he served as a Research Fellow at the ChiBioFarAm Department, University of Messina, working on the project “New therapeutic approaches for modulating inflammatory processes in central nervous system injuries and neurodegenerative diseases.”

Subsequently, from July 2024 to October 2025, he held the position of RTD-A at the University of Messina, continuing his studies on natural and synthetic compounds aimed at counteracting inflammatory and neuroinflammatory processes.

As part of his postgraduate education, he earned a Second-Level Master’s Degree in Pharmacovigilance: Safety Monitoring, Risk Management, and Quality Assurance in the Digital Health Era from the University of Milan, with a thesis entitled “DPYD6 polymorphism screening is a useful tool for decreasing gastrointestinal and hematological adverse drug reactions risk in fluoropyrimidines-treated patients.”

His research focuses on the pharmacology of inflammation, with particular attention to neuroinflammation as well as on the role of oxidative stress. He is also involved in the study of biomarkers of inflammation and drug response, and in the evaluation of novel compounds with potential anti-inflammatory and antioxidant activity, adopting a translational approach aimed at identifying innovative therapeutic strategies for diseases with high clinical and social impact.

He is the author of over 60 scientific publications indexed in Scopus and has received several awards and recognitions for the quality and originality of his research work.

He is a member of several national and international scientific societies, including the Italian Society of Pharmacology (SIF) and the British Pharmacological Society (BPS).